|
US6307025B1
(en)
|
1989-04-28 |
2001-10-23 |
Biogen, Inc. |
VCAM fusion proteins and DNA coding therefor
|
|
US5871734A
(en)
*
|
1992-01-13 |
1999-02-16 |
Biogen, Inc. |
Treatment for asthma with VLA-4 blocking agents
|
|
US5932214A
(en)
|
1994-08-11 |
1999-08-03 |
Biogen, Inc. |
Treatment for inflammatory bowel disease with VLA-4 blockers
|
|
AU688751B2
(en)
|
1993-01-12 |
1998-03-19 |
Biogen Idec Ma Inc. |
Recombinant anti-VLA4 antibody molecules
|
|
JP3593343B2
(ja)
*
|
1993-02-09 |
2004-11-24 |
バイオジェン インコーポレイテッド |
インシュリン依存型糖尿病の治療
|
|
US5840299A
(en)
*
|
1994-01-25 |
1998-11-24 |
Athena Neurosciences, Inc. |
Humanized antibodies against leukocyte adhesion molecule VLA-4
|
|
US7435802B2
(en)
|
1994-01-25 |
2008-10-14 |
Elan Pharaceuticals, Inc. |
Humanized anti-VLA4 immunoglobulins
|
|
US7750137B2
(en)
|
1995-09-01 |
2010-07-06 |
Millennium Pharmaceuticals, Inc. |
Mucosal vascular addressins
|
|
US6551593B1
(en)
|
1995-02-10 |
2003-04-22 |
Millennium Pharmaceuticals, Inc. |
Treatment of Inflammatory bowel disease by inhibiting binding and/or signalling through α 4 β 7 and its ligands and madcam
|
|
US7803904B2
(en)
|
1995-09-01 |
2010-09-28 |
Millennium Pharmaceuticals, Inc. |
Mucosal vascular addressing and uses thereof
|
|
US7147851B1
(en)
*
|
1996-08-15 |
2006-12-12 |
Millennium Pharmaceuticals, Inc. |
Humanized immunoglobulin reactive with α4β7 integrin
|
|
WO1998051345A2
(en)
*
|
1997-05-09 |
1998-11-19 |
The John P. Robarts Research Institute |
Method for dislodging infiltrated leukocytes from a tissue
|
|
DE19741235A1
(de)
|
1997-09-18 |
1999-03-25 |
Hoechst Marion Roussel De Gmbh |
Neue Imidazolidinderivate, ihre Herstellung, ihre Verwendung und sie enthaltende pharmazeutische Präparate
|
|
DE19741873A1
(de)
*
|
1997-09-23 |
1999-03-25 |
Hoechst Marion Roussel De Gmbh |
Neue 5-Ring-Heterocyclen, ihre Herstellung, ihre Verwendung und sie enthaltende pharmazeutische Präparate
|
|
DE19751251A1
(de)
|
1997-11-19 |
1999-05-20 |
Hoechst Marion Roussel De Gmbh |
Substituierte Imidazolidinderivate, ihre Herstellung, ihre Verwendung und sie enthaltende pharmezeutische Präparate
|
|
DE19821483A1
(de)
|
1998-05-14 |
1999-11-18 |
Hoechst Marion Roussel De Gmbh |
Imidazolidinderivate, ihre Herstellung, ihre Verwendung und sie enthaltende pharmazeutische Präparate
|
|
WO2000015247A2
(en)
*
|
1998-09-14 |
2000-03-23 |
Board Of Regents, The University Of Texas System |
Methods of treating multiple myeloma and myeloma-induced bone resorption using integrin antagonists
|
|
US7618630B2
(en)
|
1998-09-14 |
2009-11-17 |
Board Of Regents, The University Of Texas System |
Methods of treating multiple myeloma and myeloma-induced bone resorption using integrin antagonists
|
|
IL145898A0
(en)
*
|
1999-04-22 |
2002-07-25 |
Biogen Inc |
Method for the treatment of fibrosis using an antagonist of the integrin alpha-4 subunit
|
|
DE19922462A1
(de)
|
1999-05-17 |
2000-11-23 |
Aventis Pharma Gmbh |
Spiro-imidazolidinderivate, ihre Herstellung ihre Verwendung und sie enthaltende pharmazeutische Präparate
|
|
EE200100651A
(et)
|
1999-06-01 |
2003-02-17 |
Biogen, Inc. |
VLA-1 blokeeriv monoklonaalne antikeha ja tema kasutamine põletiku raviks
|
|
US6949245B1
(en)
|
1999-06-25 |
2005-09-27 |
Genentech, Inc. |
Humanized anti-ErbB2 antibodies and treatment with anti-ErbB2 antibodies
|
|
DK2140881T3
(da)
*
|
1999-12-16 |
2013-05-06 |
Biogen Idec Inc |
Fremgangsmåder til behandling af iskæmisk eller hæmoragisk læsion i centralnervesystemet ved anvendelse af anti-alpha-4-integrin-antagonister
|
|
DE10111877A1
(de)
|
2001-03-10 |
2002-09-12 |
Aventis Pharma Gmbh |
Neue Imidazolidinderivate, ihre Herstellung, ihre Verwendung und sie enthaltende pharmazeutische Präparate
|
|
NZ529494A
(en)
|
2001-04-13 |
2005-08-26 |
Biogen Idec Inc |
Antibodies to VLA-1
|
|
DE10137595A1
(de)
|
2001-08-01 |
2003-02-13 |
Aventis Pharma Gmbh |
Neue Imidazolidinderivate, ihre Herstellung und ihre Verwendung
|
|
NZ535320A
(en)
|
2002-02-25 |
2008-05-30 |
Elan Pharm Inc |
Administration of agents that bind to an alpha-4 integrin for the treatment of inflammation
|
|
CA2481747A1
(en)
*
|
2002-04-12 |
2003-10-23 |
Medimmune, Inc. |
Recombinant anti-interleukin-9 antibodies
|
|
GB0210121D0
(en)
*
|
2002-05-02 |
2002-06-12 |
Celltech R&D Ltd |
Biological products
|
|
AR040778A1
(es)
*
|
2002-08-06 |
2005-04-20 |
Glaxo Group Ltd |
Anticuerpos alterados o fragmentos funcionales que se unen a mag (glicoproteina asociada a mielina).
|
|
AU2003298187B2
(en)
*
|
2002-12-17 |
2010-09-16 |
Merck Patent Gmbh |
Humanized antibody (H14.18) of the mouse 14.18 antibody binding to GD2 and its fusion with IL-2
|
|
CU23403A1
(es)
*
|
2003-04-23 |
2009-08-04 |
Centro Inmunologia Molecular |
Anticuerpos recombinantes y fragmentos que reconocen el gangliósido n-glicolil gm3 y su uso para diagnóstico y tratamiento de tumores
|
|
WO2005061466A1
(ja)
|
2003-12-22 |
2005-07-07 |
Ajinomoto Co., Inc. |
新規フェニルアラニン誘導体
|
|
CN103169965A
(zh)
*
|
2004-11-19 |
2013-06-26 |
比奥根艾迪克Ma公司 |
治疗多发性硬化
|
|
WO2007061679A1
(en)
*
|
2005-11-17 |
2007-05-31 |
Millennium Pharmaceuticals, Inc. |
HUMANIZED IMMUNOGLOBULIN REACTIVE WITH α4β7 INTEGRIN
|
|
CN105381459A
(zh)
|
2006-05-25 |
2016-03-09 |
比奥根Ma公司 |
治疗中风的方法
|
|
EP2510941A3
(en)
|
2007-02-20 |
2013-01-23 |
Merrimack Pharmaceuticals, Inc. |
Methods of treating multiple sclerosis by administration of alpha-fetoprotein in combination with an integrin antagonist
|
|
US20080311119A1
(en)
*
|
2007-06-14 |
2008-12-18 |
Biogen Idec Ma Inc. |
Antibody formulations
|
|
BRPI0820202B1
(pt)
|
2007-12-13 |
2018-05-08 |
Tokuyama Corp |
composição curável fotocrômica
|
|
ES2525065T3
(es)
|
2008-04-11 |
2014-12-17 |
Merrimack Pharmaceuticals, Inc. |
Ligadores de seroalbúmina humana y sus conjugados
|
|
MY162752A
(en)
|
2009-03-20 |
2017-07-14 |
Amgen Inc |
Alpha-4-beta-7 heterodimer specific antagonist antibody
|
|
US20120258093A1
(en)
|
2009-08-20 |
2012-10-11 |
Institut National De La Sante Et De La Recherche Medicale (Inserm) |
Vla-4 as a biomarker for prognosis and target for therapy in duchenne muscular dystrophy
|
|
ME02793B
(me)
|
2010-04-16 |
2018-01-20 |
Biogen Ma Inc |
Anti-vla-4 antitijela
|
|
CA2834900C
(en)
|
2011-05-02 |
2021-03-02 |
Millennium Pharmaceuticals, Inc. |
Formulation for anti-.alpha.4.beta.7 antibody
|
|
UA116189C2
(uk)
|
2011-05-02 |
2018-02-26 |
Мілленніум Фармасьютікалз, Інк. |
КОМПОЗИЦІЯ АНТИ-α4β7 АНТИТІЛА
|
|
MX370199B
(es)
|
2012-02-16 |
2019-12-05 |
Santarus Inc |
Composiciones farmaceuticas de anticuerpo anti-antigeno muy tardio (cd49a).
|
|
US20190225694A1
(en)
|
2016-06-28 |
2019-07-25 |
Zaklady Farmaceutyczne Polpharma Sa |
Recombinant production of monoclonal antibodies
|
|
US20190374639A1
(en)
|
2016-11-21 |
2019-12-12 |
Polpharma Biologics S.A. |
Aqueous pharmaceutical formulations
|
|
EP3583126B1
(en)
*
|
2017-02-17 |
2025-08-27 |
Sanofi |
Multispecific binding molecules having specificity to dystroglycan and laminin-2
|
|
WO2018224673A1
(en)
|
2017-06-08 |
2018-12-13 |
Zaklady Farmaceutyczne Polpharma S.A. |
Improved methods of cell culture
|
|
EP3800999A4
(en)
|
2018-06-04 |
2022-06-01 |
Biogen MA Inc. |
ANTI-VLA-4 ANTIBODY WITH REDUCED EFFECTIVE FUNCTION
|
|
WO2022162164A1
(en)
|
2021-01-29 |
2022-08-04 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods of assessing the risk of developing progressive multifocal leukoencephalopathy in patients treated with vla-4 antagonists
|